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Abstract
Background: The aim of this work is to develop an algorithm to predict recurrence in prostate cancer patients
treated with radical radiotherapy, getting up to a prognostic power higher than traditional D’Amico risk classification.
Methods: Two thousand four hundred ninety-three men belonging to the EUREKA-2 retrospective multi-centric
database on prostate cancer and treated with external-beam radiotherapy as primary treatment comprised the
study population. A Cox regression time to PSA failure analysis was performed in univariate and multivariate
settings, evaluating the predictive ability of age, pre-treatment PSA, clinical-radiological staging, Gleason score
and percentage of positive cores at biopsy (%PC). The accuracy of this model was checked with bootstrapping
statistics. Subgroups for all the variables’ combinations were combined to classify patients into five different
“Candiolo” risk-classes for biochemical Progression Free Survival (bPFS); thereafter, they were also applied to
clinical PFS (cPFS), systemic PFS (sPFS) and Prostate Cancer Specific Survival (PCSS), and compared to D’Amico
risk grouping performances.
Results: The Candiolo classifier splits patients in 5 risk-groups with the following 10-years bPFS, cPFS, sPFS and
PCSS: for very-low-risk 90 %, 94 %, 100 % and 100 %; for low-risk 74 %, 88 %, 94 % and 98 %; for intermediate-risk
60 %, 82 %, 91 % and 92 %; for high-risk 43 %, 55 %, 80 % and 89 % and for very-high-risk 14 %, 38 %, 56 % and
70 %. Our classifier outperforms D’Amico risk classes for all the end-points evaluated, with concordance indexes
of 71.5 %, 75.5 %, 80 % and 80.5 % versus 63 %, 65.5 %, 69.5 % and 69 %, respectively.
Conclusions: Our classification tool, combining five clinical and easily available parameters, seems to better
stratify patients in predicting prostate cancer recurrence after radiotherapy compared to the traditional
D’Amico risk classes.
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Background
Prostate cancer (PCa) is the most common cancer in
men and the second most common cause of death
from tumors in males [1]. Several nomograms have
been developed to guide therapy and predict outcome
following radiotherapy: one of the most popular clas-
sifications is the D’Amico risk classifier, dividing pa-
tients according to pre-treatment PSA, clinical stage
and biopsy-based Gleason score (bGS) into three cat-
egories: low-risk (PSA <10 ng/ml and cT1-cT2a and
bGS ≤6) , intermediate-risk (PSA 10–20 ng/ml or cT2b or
bGS 7) and high-risk (PSA >20 ng/ml or clinical stage ≥
cT2c or bGS ≥8) [2].
Several additional pathological, clinical-radiological
and molecular markers have been studied in the past 15
years to implement D’Amico classification [3]: of these,
the simplest and more readily available information are
age at treatment and the percentage of positive biopsy
cores (%PC). In 2000–2001, D’Amico reported the inde-
pendent prognostic ability of %PC to foresee biochem-
ical recurrence beyond traditional risk factors in a
radical prostatectomy cohort of 823 men [4] and in 473
men treated by external-beam radiotherapy (EBRT) [5].
Regarding age, Siddiqui [6] reported in a radical prosta-
tectomy cohort of 5509 men a higher risk of systemic
progression and death from prostate cancer in patients
younger than 55 compared to patients older than 70. In
addition, Ribeiro [7] confirmed that age lower than 60
predicts for a poor outcome (time to progression and
overall survival) in metastatic prostate cancer receiving
androgen deprivation therapy (ADT).
In our study, based on a large database of thousands of
patients affected by prostate cancer and treated with
EBRT, we developed a 5-classes nomogram for predicting
biochemical Progression Free Survival (bPFS) including
not only pre-treatment PSA, stage and bGS, but also age
and %PC. Thereafter, we applied it to predict clinical PFS
(cPFS), systemic PFS (sPFS) and Prostate Cancer Specific
Survival (PCSS) too, and compared the performance of
our nomogram with the D’Amico risk classification.
Methods
Patient population
Two thousand four hundred ninety three men affected
by prostate cancer and treated with EBRT as primary
treatment comprised the study population.
This cohort belongs to the EUREKA-2 retrospective
multi-centric database, including 3776 cases of radio-
treated prostate cancer cases in North-West Italy be-
tween 1997 and 2012, approved by FPO-IRCCS Cancer
Center of Candiolo Ethical Committee in July 2013 and
amended in November 2014. Ten Radiotherapy Divi-
sions participated to EUREKA-2 study, seven of which
in Piedmont Italian region, two in Lombardy and one in
Tuscany (full information are provided in Additional file
1: Table S1). Inclusion criteria for EUREKA-2 study
were: histologic diagnosis of adenocarcinoma of the
prostate; Radical Radiotherapy as first-line treatment,
performed with conformational technique within the
period January 1st, 1997 to December 31st, 2012; at least
two of the following three pre-treatment parameters:
PSA, staging, Gleason Score; case histories, clinical and
serological follow-ups available for clinical data collec-
tion. Concerning privacy procedures, data were pseudo-
anonymized by local researchers within the participating
Hospitals. The two lists with patients’ personal data and
clinical data were kept separated and only clinical data,
and not personal data, were sent to EUREKA-2 common
database. Consequently, outside the hospitals and in the
common EUREKA-2 database data are anonymous and
by no way amenable to the single patient identity. The
files are stored with Microsoft Excel and Microsoft
Access data management software (®MicroSoft Corpor-
ation, Redmond, Washington, USA) according to differ-
ent domains: socio-demographic group of data, biopsy
and staging, therapies, oncologic outcomes, serologic
follow-up and collateral effects.
In particular, from the whole EUREKA-2 database
were excluded 1283 patients without complete informa-
tion regarding established pre-treatment factors (PSA,
clinical-radiologic stage and bGS) and the number of
total and positive biopsy cores.
Preoperative staging and treatment
In all cases, staging evaluation included anamnesis,
physical exam with Digital Rectal Examination (DRE),
serum PSA and a trans-rectal ultrasound (TRUS) guided
needle biopsy of the prostate with GS histologic grading.
Radiological examinations (abdominal CT, endo-coil or
pelvic MRI and bone scan) were performed according to
the patient risk-class, to the physician’s opinion and to
the available hospital facilities.
PSA was obtained before biopsy and radiologic studies.
Primary, secondary and total GS were mainly attributed
according to ISUP 2005 revised Gleason Score system
[8]. The clinical-radiologic stage was obtained integrat-
ing the clinical AJCC 2010 staging system [9] with all
the radiologic information available, while biopsy data
were not taken into account. Age at treatment was cal-
culated as the difference between the first day of radio-
therapy and the date of birth, rounded to the closest
integer number. The %PC was calculated multiplying
100 by the number of positive cores containing prostate
cancer, of any length, and dividing by the total number
of cores sampled.
All patients were treated with curative 3-Dimensional
Conformal EBRT (3D-CRT) or Intensity Modulated Ra-
diation Therapy (IMRT). The fractionation schedules to
Gabriele et al. Radiation Oncology  (2016) 11:23 Page 2 of 10
prostate-GTV (Gross Tumor Volume) varied between
traditional fractionation of 1.8-2 Gy per fraction to mod-
erate hypo-fractionation of 2.5-2.7 Gy per fraction; all
doses were normalized to Equivalent Dose at 2 Gy per
fraction (ED2Gy) using a mean α/β of 2.5 Gy for pros-
tate cancer (according to literature α/β ratio for prostate
cancer ranges between 1.5 and 5.7 Gy [10–12]). Treat-
ment consisted of radiotherapy alone or radiotherapy
combined with ADT in 38 % and 62 % of the cases,
respectively.
Follow-up
Median follow-up of the 2493 patients was 50 months.
Standard follow-up included PSA and DRE every 3-
months for 2 years, every 6-months until the fifth year
and annually thereafter.
During the follow-up 453 patients (18 %) had a bio-
chemical relapse, 249 (10 %) relapsed clinically, 138
(5.5 %) had distant metastases, and 233 (9 %) died,
72 of these (3 % of the total) because of prostate cancer.
Time 0 was defined as the last day of EBRT for all pa-
tients and PSA failure according to Phoenix consensus
definition (i.e. a rise by 2 ng/mL or more above the nadir
PSA [13]). Clinical relapse was defined as a recurrence
in the prostate bed, regional lymph nodes or distant me-
tastasis shown by radiologic examinations (bone scan,
choline-PET-CT, MRI, CT, ultrasound) or by physical
examination or by biopsy. Systemic relapse was defined
as a distant metastasis, including bone or other visceral
organs, shown by radiologic examinations or by physical
examination. Prostate cancer specific mortality was de-
fined as death because of prostate cancer, checked by a
physician through patients’ case history reports, cancer
regional registries and, if necessary, phone calls to the
patient or to a close relative or General Practitioner of
him (if the patient was dead).
Statistical analyses
A Cox regression time to PSA failure analysis was per-
formed in univariate and multivariate settings, evaluating
the predictive ability of age, pre-treatment PSA, clinical-
radiological stage, GS and %PC; besides, the regression
algorithm was adjusted for RT dose (as a continuous
variable) and combined therapy (RT + ADT or RT alone,
as a dichotomous variable). The assumptions of the Cox
model were tested and met.
All variables were evaluated as categorical variables:
age ≥70 years or age <70 years; PSA <7 ng/ml, 7–15 ng/
ml, or >15 ng/ml; clinical-radiologic stage cT1, cT2 or
cT3-cT4; bGS ≤6, 3 + 4, 4 + 3, 8 or 9–10; %PC 1-20 %,
21-50 %, 51-80 % or 81-100 %.
Effects cell coding (i.e. 1 or 0 or −1 coding) was ap-
plied to the stratified variables, in order to calculate the
relative Hazard Ratios (HRs) of the multivariate analysis
compared to the outcome of the mean of the cohort.
The accuracy of the model was checked with bootstrap-
ping statistics (2493 patients, resampling with 1000 cases
each replication for a total of 10,000 replications).
A 360-cells-table was built by multiplying the HRs of
the subgroups for all the variables’ combinations; the fol-
lowing combined HRs were classified into 5 different
risk classes for biochemical relapse: very-low-risk for
HRs 0.17-0.30; low-risk for HRs 0.31-0.55; intermediate-
risk for HRs 0.56-1.20; high-risk for HRs 1.21-2.40; and
very-high-risk for HRs 2.41-6.60. In addition, an equiva-
lent nomogram was built multiplying 100 by the beta co-
efficients associated to the HRs, normalizing each
reference value of the variables to 0 points (i.e. age ≥70,
PSA <7 ng/ml, stage cT1, bGS ≤6 and %PC 1-20 %), and
summing up the values of the 5 prognostic factors into a
scale ranging in between 0 and 363 total points, corre-
sponding to the previously defined 5 risk classes.
Kaplan-Meier survival curves for bPFS, divided ac-
cording to our 5-risk-classes and to D’Amico risk classes
(for comparison), were graphed, overall and paired log-
rank tests were performed and Concordance Indexes
calculated. In addition, D’Amico risk classification and
our 5-groups classification tool were further analyzed for
cPFS, sPFS and PCSS and their prediction performances
compared.
All statistical analyses were performed with Stata SE
13.1 Software (®StataCorp, Texas, USA).
Results
The stage and treatment characteristics of the 2493 pa-
tients are listed in Table 1.
All variables evaluated, i.e. age, pre-treatment PSA,
clinical-radiologic stage, bGS and %PC are highly signifi-
cant predictors of biochemical relapse in both univariate
and multivariate Cox models: all Ps are lower than 0.001
except for age, whose values are P = 0.001 and P = 0.019
in univariate and multivariate analyses, respectively
(Table 2). In particular, the risk of recurrence rises in
younger patients and increases gradually with higher
PSA, wider clinical-radiologic extension in/out prostate,
higher bGS and a higher percentage of biopsy cores af-
fected by cancer. Internal validation performed with
bootstrapping shows a good reliability of the model as a
whole: PSA and bGS remain highly significant (P < 0.001
and P = 0.012, respectively), %PC and clinical-radiologic
stage are significant (P = 0.008 and P = 0.031), while
age shows a trend but loses its statistical significance
(P = 0.16; see Table 2 last column).
The 360-cells-table combining all the possible combi-
nations of the stratified parameters clearly shows a
strong trend, going from very-low risk (in blue) on the
upper-left corner to very-high-risk (in red) in the lower-
right corner; in between can be noticed low-risk (in
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green), intermediate-risk (in yellow) and high-risk (in or-
ange, see Table 3 and Additional file 1: Table S2). Very-
low-risk group includes 529 patients (21 %), low-risk
770 (31 %), intermediate risk 696 (28 %), high-risk 329
(13 %) and very-high risk 169 (7 %); full data on patients’
distribution according to model parameters are illus-
trated in (Additional file 1: Table S3). Besides, the related
Candiolo nomogram is displayed in Fig. 1.
In Fig. 2 are shown the Kaplan-Meier curves for bPFS
(a-e), cPFS (b-f ), sPFS (c-g) and PCSS (d-h) according to
D’Amico risk classification (a-b-c-d) or to Candiolo clas-
sifier (e-f-g-h) with overall and paired log-rank-test re-
sults. The Concordance Indexes for Candiolo nomogram
are 71.5 %, 75.5 %, 80 % and 80.5 % for bPFS, cPFS, sPFS
and PCSS, respectively, consistently higher than
D’Amico ones (63 %, 65.5 %, 69.5 % and 69 %,
respectively).
In addition, Table 4 resumes yearly (until 10 years of
follow-up) bPFS, cPFS, sPFS and PCSS for the five-
classes of the Candiolo classifier. In particular, bPFS
ranges at 5-yy between 94 % (very-low-risk) and 43 %
(very-high-risk) and at 10-yy between 90 % and 14 %;
cPFS varies at 5-yy between 97 % and 62 % and at 10-yy
between 94 % and 38 %; sPFS ranges at 5-yy between
100 % and 71 % and at 10-yy between 100 % and 56 %;
PCSS ranges at 5-yy between 100 % and 86 % and at 10-
yy between 100 % and 70 %.
Discussion
The Candiolo classifier differs significantly from the
D’Amico risk classification. As far as pre-treatment PSA
is concerned, D’Amico advises the cut-offs of 10 and 20
ng/ml, while our optimal boundaries are slightly lower: 7
and 15 ng/ml. Probably the difference relies in the co-
hort, our whole patients pertaining to post-PSA screen-
ing era; but also in the introduction of percentage of
positive cores as a covariate, carrying a second informa-
tion about cancer extension and therefore able to shift
the best stratification cut-offs.
Concerning bGS, we definitely refined the traditional
coarse classification in 3-classes (≤6, 7 or ≥8) dividing
Table 1 Characteristics of our series of 2493 patients
Features
Follow-up, months
Mean (SD) 56 (36)
Median (Min-Max) 50 (4–159)
FU ≥ 2-yy, no (%) 2018 (81 %)
FU ≥ 5-yy, no (%) 982 (39 %)
FU ≥ 7-yy, no (%) 481 (19 %)
FU ≥ 10-yy, no (%) 179 (7 %)
Age, yr
Mean (SD) 71.7 (5.9)
Median (Min-Max) 73 (43–86)
PSA, ng/ml
Mean (SD) 15.0 (26.0)







Not performed 33 %
Abdominal CT staging
Performed 59 %
Not performed 41 %
Endo-coil or pelvic MRI staging
Performed 15 %
Not performed 85 %
TRUS
Performed 49 %
Not performed 51 %
Biopsic Gleason Score, %
≤6 48 %
3 + 4 22 %
4 + 3 11.5 %
8 12 %
9-10 6.5 %




Biopsy cores sampled, no
Mean (SD) 10.3 (4.2)
Median (Min-Max) 10 (2–42)
% Positive Cores, %
Mean (SD) 44.3 % (28.0 %)
Table 1 Characteristics of our series of 2493 patients
(Continued)
Median (Min-Max) 40 % (3-100 %)
RT Dose, ED2Gy
Mean (SD) 75.5 (3.0)
Median (Min-Max) 76.0 (67.1-81.1)
RT alone, % 38 %
RT plus ADT, % 62 %
SD Standard deviation, TRUS Trans rectal ultra-sound, ED2Gy Equivalent dose
at standard 2 Gy dose per fraction, RT Radiation therapy, ADT Androgen
deprivation therapy
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Table 2 Univariate and multivariate cox regression (time to PSA failure) and bootstrapping analysis
Variables Sub-groups Univariate analysis Multivariate analysis Bootstrapping
HR P value HR P value P value
Age ≥70 yy 0.85 0.001 0.89 0.019 0.16
<70 yy 1.18 1.12
PSA <7 0.52 <0.001 0.63 <0.001 <0.001
7-15 0.88 0.96
>15 2.17 1.65
Staging cT1 0.49 <0.001 0.77 <0.001 0.031
cT2 0.95 0.93
cT3-4 2.17 1.40
bGS ≤6 0.47 <0.001 0.59 <0.001 0.012
3 + 4 0.77 0.83
4 + 3 0.99 0.95
8 1.31 1.26
9-10 2.13 1.70
% Positive Cores 1-20 % 0.48 <0.001 0.67 <0.001 0.008
21-50 % 0.76 0.89
51-80 % 1.22 1.11
81-100 % 2.26 1.50
RT Dose Continuous 0.88 / Gy <0.001 0.89 / Gy <0.001 0.001
Therapy schedule RT alone 0.81 <0.001 1.25 <0.001 0.028
RT & ADT 1.24 0.80
Table 3 Candiolo classifier table: very-low-risk blue, low-risk green, intermediate-risk yellow, high-risk orange, very-high-risk red
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patients according to a more precise 5-classes layering,
in particular discerning 3 + 4 versus 4 + 3 patterns and
8 versus 9–10 ones. Taking ISUP 2005 modified Gleason
Score as a time cut-off [8], i.e. comparing patients
treated up to 2004 (569 cases) versus 2005 onwards
(1924 patients), there is an almost significant time trend
concerning total biopsic Gleason Score with bGS means
increasing from 6.5 to 6.7, respectively (both medians
are equal to 7, P = 0.06 at Wilcoxon-Mann–Whitney
test). However, we think this trend does not affect sub-
stantially our nomogram because of three main reasons:
the difference in absolute terms is quite small, the num-
ber of patients treated prior to ISUP 2005 Gleason Score
revision is only 23 % of the total, and finally we reduced
the under-grading influence in older cases (in which
total bGS of 2-3-4 were much more frequent) by com-
bining together all bGS ≤ 6 into a single risk category.
Considering staging, the D’amico clinical staging, split-
ting patients according to their cT2 stage (≤cT2a, cT2b
or ≥ cT2c) was replaced by a clinical and radiological
staging taking advantage of radiologic information and
dividing patients according to more objective criteria:
cT1 microscopic cancer, cT2 macroscopic but intra-
prostatic cancer, cT3-4 macroscopic and extra-prostatic
adenocarcinoma. Actually, Epstein [14] found, even if in
a radical prostatectomy cohort, that pT2b staging almost
doesn’t exist and that data are conflicting about the
power of pT2 disease sub-staging to further stratify pa-
tients. According to Algarra [15] MRI data optimize
D’Amico risk groups in predicting bPFS after radical
prostatectomy. Unfortunately, only 15 % of our pa-
tients were locally staged through MRI (we calculated
with logistic regression a strong association between
MRI staging and T3 with an OR = 6.98 and a P < 0.001).
However, this relationship may be over-estimated because
of a selection bias (MRI is performed usually in suspect of
extra-prostatic extension) and it may be partially compen-
sated by the widespread execution of CT and ultra-sound
in 59 % and 49 % of our patients, respectively; precisely,
the percentage of patients having neither CT nor MRI for
loco-regional staging decreases in our cohort to 35 %.
In addition, we added %PC and age in the prognostic
algorithm. The prognostic significance of tumor volume
has been tested both in radical prostatectomy and needle
biopsy specimens. Therefore, it is recommended to rec-
ord at least the number of positive and total cores along
with one other more detailed measurement such as the
percent of the core involvement or length of cancer [14].
Besides, in 2007 Briganti [16] showed that %PC can im-
prove the ability to predict lymph nodes invasion in pa-
tients undergoing radical prostatectomy and extended
pelvic lymph node dissection: %PC and bGS were the
most informative predictors of Lymph Node Involve-
ment, overcoming PSA and stage. The addition of %PC
to a nomogram including traditional risk factors was
able to improve overall accuracy from 79.7 % to 83 %
(P < 0.001). In the early 2000s, D’Amico clearly
proved the independent value of positive prostate bi-
opsies in predicting biochemical outcome after radical
prostatectomy [4] or after EBRT [5]. The information
Fig. 1 Candiolo nomogram. Points: bGS ≤ 6 0 pt, bGS = 3 + 4 35 pt, bGS = 4 + 3 48 pt, bGS = 8 76 pt, bGS = 9-10 106 pt; cT1 0 pt, cT2 17 pt,
cT3-4 58 pt; PSA < 7 0 pt, PSA7-15 42 pt, PSA > 15 96 pt; %PC 1-20 % 0 pt, 21-50 % 29 pt, 51-80 % 50 pt, 81-100 % 81 pt; age ≥ 70 0 pt, age < 70 22
pt; very-low risk 0–56 pt, low risk 57–116 pt, intermediate risk 117–193 pt, high risk 194–262 pt, very-high risk 263–363 points
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Fig. 2 bPFS (a-e), cPFS (b-f), sPFS (c-g) and PCSS (d-h) according to D’Amico classification (a-b-c-d) or to Candiolo classifier (e-f-g-h). Kaplan-Meier
curves with overall and paired log-rank-test results, and Concordance Indexes in bold
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about tumor extension at biopsy was clinically signifi-
cant to better classify intermediate-risk patients; in
both studies patients were stratified in three classes:
%PC < 34 %, 34-50 %, %PC > 50 %. In 2004 D’Amico
[17] further showed that %PC was superior to trad-
itional risk factors in predicting prostate cancer spe-
cific mortality (PCSM) in patients with low or
favorable intermediate-risk; the relative risk of PCSM
for patients with %PC ≥ 50 % as compared with <50 %
was 10.4. However, Kupka [18] reported in a cohort of 249
men treated with RP that even prostate cancer with
single positive core is associated with considerable
rates of over-grading for the pathological GS, pT2c-
pT3 and positive surgical margin. Therefore, %PC
should not be used alone to predict patients’ progno-
sis after radical therapy, and treatment plan has al-
ways to take into account the traditional prognostic
factors, too. Therefore, several reports and our ana-
lysis strongly support the statistical significance of
%PC as an additional prognostic factor of prostate
cancer recurrence.
Literature is more scarce concerning age, showing for
older patients a lower rate of distant metastases or pros-
tate cancer deaths, but not an advantage in biochemical
relapse [6, 7]. The finding is confirmed by our data,
where the statistical significance of the variable age was
the lowest between the selected prognostic factors of
biochemical recurrence and failed the internal validation
with bootstrapping. However, its relevance may be much
more powerful for late end-points like sPFS and PCSS,
and so this could be one of the determinant factors of
the higher concordance indexes for these end-points by
the Candiolo classifier (around 80 %). In fact, two main
reasons can justify the worse prognosis of younger
Table 4 Life tables: bPFS, cPFS, sPFS and PCSS for the five-classes of the Candiolo classifier
Candiolo risk class Biochemical PFS – follow-up (years)
1 2 3 4 5 yy 6 7 8 9 10 yy
Very-Low 99 % 99 % 96 % 95 % 94 % 92 % 90 % 90 % 90 % 90 %
Low 99 % 97 % 94 % 90 % 85 % 84 % 82 % 80 % 76 % 74 %
Intermediate 98 % 94 % 90 % 83 % 80 % 74 % 69 % 65 % 63 % 60 %
High 95 % 85 % 78 % 71 % 67 % 60 % 54 % 52 % 47 % 43 %
Very-High 83 % 72 % 60 % 51 % 43 % 36 % 35 % 31 % 23 % 14 %
Candiolo Risk Class clinical PFS – Follow-up (years)
1 2 3 4 5 yy 6 7 8 9 10 yy
Very-Low 100 % 100 % 99 % 99 % 97 % 97 % 96 % 94 % 94 % 94 %
Low 99 % 99 % 98 % 96 % 94 % 92 % 91 % 89 % 88 % 88 %
Intermediate 99 % 97 % 95 % 93 % 92 % 89 % 87 % 85 % 85 % 82 %
High 98 % 93 % 89 % 84 % 79 % 76 % 68 % 66 % 63 % 55 %
Very-High 89 % 81 % 74 % 68 % 62 % 56 % 53 % 51 % 42 % 38 %
Candiolo Risk Class systemic PFS – Follow-up (years)
1 2 3 4 5 yy 6 7 8 9 10 yy
Very-Low 100 % 100 % 100 % 100 % 100 % 100 % 100 % 100 % 100 % 100 %
Low 100 % 100 % 99 % 98 % 97 % 97 % 96 % 95 % 94 % 94 %
Intermediate 100 % 98 % 97 % 95 % 94 % 93 % 92 % 91 % 91 % 91 %
High 99 % 95 % 93 % 90 % 89 % 88 % 82 % 82 % 80 % 80 %
Very-High 90 % 82 % 77 % 73 % 71 % 68 % 66 % 64 % 60 % 56 %
Candiolo Risk Class PCSS – Follow-up (years)
1 2 3 4 5 yy 6 7 8 9 10 yy
Very-Low 100 % 100 % 100 % 100 % 100 % 100 % 100 % 100 % 100 % 100 %
Low 100 % 100 % 99 % 99 % 99 % 99 % 98 % 98 % 98 % 98 %
Intermediate 100 % 100 % 99 % 98 % 98 % 98 % 96 % 95 % 95 % 92 %
High 100 % 99 % 99 % 96 % 95 % 93 % 93 % 92 % 89 % 89 %
Very-High 99 % 95 % 92 % 87 % 86 % 80 % 80 % 76 % 70 % 70 %
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patients: intrinsic biologic differences of prostate cancer
and variations in patient’s hormonal status at different
ages, and a greater likelihood of experiencing progres-
sion or death since they are less likely to die of compet-
ing comorbidity conditions. We chose the 70 years cut-off
according to a previous paper of our research group at
FPO-IRCCS Cancer Center of Candiolo, published by
Maggio et al. in 2012 [19]. It showed that patients older
than 70 years have better outcomes compared with youn-
ger ones, and precisely that, at 90 months of follow-up,
Overall Survival and Disease-Free Survival (biochemical
and clinical) were 10 % and 16 % higher in older patients,
respectively; besides, there was no significant difference in
the distribution of pre-RT risk-classes between age groups.
Moreover, the 70 years cut-off is clinically useful because
next to the median and mean ages of our cohort, that are
73 and 71.7 years, respectively.
Our five classes are statistically different at paired
comparisons for bPFS, cPFS, sPFS, while for PCSS three
main groups may be identified: very-low and low-risk to-
gether (summing up to 52 % of the overall cohort) with
almost no dead at 10 years, intermediate and high-risk
with a specific mortality at 10-yy around 10 % and very-
high-risk alone with a 10-yy mortality of 30 %.
The mean prostate cancer specific survival in our
cohort at 5 and 10 years are 97.5 % and 92.5 %, re-
spectively. These high values may be justified by the
intense therapy, performed both as a first-line treat-
ment (62 % of the cases where treated with the com-
bination RT + ADT) and/or as a salvage or palliative
therapy after biochemical and/or clinical recurrence
(ADT alone 82 %, chemotherapy 3 %, local therapies
i.e. surgery, RT, HIFU and cryotherapy 6 %, ADT plus
local therapy 3 %, none 6 %).
The main strengths of our study are: the large
numerosity of our sample (2493 patients), widely dis-
tributed according to risk factors combinations (e.g.
PSA from <1 to >100 ng/ml), and with complete sta-
ging and treatment information; the integration of
five significant prognostic factors according to all
their possible combinations; the five-risk classification
instead of three-risk-classes with wider prognostic dif-
ferences; the Proportional Hazard assumption of the
Cox model fulfilled (see in the Additional file 1: Figure
S1); the internal validation with bootstrapping performed;
the nomogram, developed with bPFS as setting end-point,
was successfully applied to other three following out-
comes, i.e. cPFS, sPFS and PCSS.
On the other hand, our study has several limitations,
mainly related to its retrospective and multi-centric na-
ture, and to the absence of an external validation. In par-
ticular, the biopsy schemes adopted by each center were
heterogeneous and there wasn’t any central pathologic
review (even if by a decade Piedmont Oncology Web
fosters pathology quality assessment on prostate cancer
through guidelines and periodic meetings [20, 21]). Fur-
thermore, radiologic staging protocols changed in time
with a low total number of MRI, as well as the RT
prescription doses, fractionation schedules and the
use of combined therapy with ADT; and median
follow-up of 50 months is still short for a “slow
killer” like prostate cancer. Besides, the model applied
was a simple linear regression with no interaction fac-
tors considered: it allows the modelling to be simple
and robust, but does not take into consideration more
complex modelling. In addition, an external validation
is needed as soon as possible.
Conclusions
In conclusion, our study develops a new risk classifica-
tion tool, that we called the “Candiolo classifier”, in a
wide cohort of radio-treated patients at higher risk of re-
lapse (46.5 % of our cases are in D’Amico high-risk
group versus 21 % of D’Amico early 2000s studies [4, 5])
treated with higher doses of RT (median dose of 76 Gy
versus 70.2 Gy of the D’Amico studies) and treated with
RT + ADT in 62 % of cases. Besides, we subdivided our
patients into five different classes instead of three, with
Concordance Indexes around 10 % higher in foreseeing
bPFS, cPFS, sPFS and PCSS.
We would like to evidence some points about our
5-classes distribution. First, even rare 3 + 4 or 4 + 3
cancers with all other positive factors may be in-
cluded in very-low-risk group. Second, a quite high
number of patients (21 %) can be classified in very-
low risk class with 100 % sPFS and PCSS at 10 years,
and can be of consequence selected for watchful waiting
approach too. Third, only a restricted number of patients
(7 % of the total) belong to very-high-risk class, with 30 %
of prostate cancer specific deaths at 10 years.
We further recommend the development of a nomo-
gram integrating in this subset of patients also thera-
peutic information (RT dose and ADT) and the
enhancement of a tailored follow-up schedule according
to the risk of recurrence.
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